Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Cidara - The Real Truth

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything

Merck's multi-billion-dollar acquisition of Cidara Therapeutics is a strategic move to secure a new era of growth with a high-potential antiviral asset.

MarketBeat · Nov 18, 2025

Merck Makes Big Bet On Flu Protection With Cidara Buyout

Merck Co. Inc. (NYSE:MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ:CDTX) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.

Benzinga · Nov 14, 2025

Why Is Cidara Therapeutics (CDTX) Stock Trending Overnight?

Cidara Therapeutics Inc. (NASDAQ:CDTX) shares are trending on Friday.

Benzinga · Nov 14, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage

Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement about their presentation at the upcoming ESWI 2025 conference. JP Morgan also initiated coverage of the stock, assigning it an Overweight rating and setting a price target of $200.

Benzinga · Oct 10, 2025

Cidara Shares Are Trading Higher Friday: What's Going On?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic influenza therapeutic and onshore its manufacturing.

Benzinga · Oct 3, 2025

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?

MarketBeat · Jun 30, 2025

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Benzinga · Sep 13, 2022

Read news from The Economist, FT, and more,
with one subscription

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Benzinga · Jul 27, 2022

Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock

U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch.

Benzinga · May 12, 2022

FDA Clears Cidara Therapeutics' Phase 1 Trial For Immunotherapeutic Antiviral For Influenza

The

Benzinga · Feb 14, 2022

Coverage From

Organisations

Food and Drug Administration

European Medicines Agency

77 stories

Amgen Inc

76 stories

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Europe

41,828 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.